

IFW



Patent
39038.00002.CIP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:)
Sylvain, Chemtob et al.) Group Art Unit: 1614
Serial No.: 10/678,413) Examiner: To be assigned
Filed: October 02, 2003) Customer No.: 36183
For: G PROTEIN-COUPLED RECEPTOR)
AGONISTS OR ANTAGONISTS)

TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Enclosed are the following documents:

- Supplemental Information Disclosure Statement;
- Form PTO/SB/08A; and
- Return Postcard;

No fee is believed due with this submission; however, the Commissioner is authorized to charge any fee required to our Deposit Account No. **50-2613**.

CERTIFICATE OF MAILING
(37 C.F.R. §1.8a)

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

September 23, 2004
Date of Deposit
SAN/98153.1

Timothy Lasher
Name of Person Mailing Paper

T.Lasher
Signature of Person Mailing Paper

Patent
39038.00002.CIP


Respectfully submitted,

PAUL, HASTINGS, JANOFSKY & WALKER LLP

Dated:

Sept 23, 2007

By:


Jane K. Babin
Reg. No. 47,224


PAUL, HASTINGS, JANOFSKY & WALKER LLP

P.O. Box 919092

San Diego, CA 92191-9092

Phone: (858) 720-2500

Fax: (858) 720-2555



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Sylvain, Chemtob et al.

Serial No.: 10/678,413

Filed: October 02, 2003

For: G PROTEIN-COUPLED RECEPTOR
AGONISTS OR ANTAGONISTS

) Group Art Unit: 1614

) Examiner: To be assigned

) Customer No.: 36183

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the Applicant's duty under 37 CFR § 1.56, the following information is brought to the attention of the Examiner.

CERTIFICATE OF MAILING
(37 CFR §1.8 a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

September 23, 2004

Date of Delivery

Timothy Lasher
Name of Person Delivering Paper

Timothy Lasher
Signature of Person Delivering Paper

REFERENCES



The references are listed on the attached Form PTO/SB/08a and copies are enclosed for the convenience of the Examiner.



Copies of the references listed on the attached Form PTO/SB/08a have already been submitted in corresponding Patent Application No. 09/783,334 & 09/154,627 and therefore, copies of the same are not enclosed.



Pursuant to the Patent Office waiver of 37 C.F.R. 1.98(a)(2)(i)
(<http://www.uspto.gov/web/offices/pac/dapp/opla/preognotice/idswouscopies.htm>), copies of U.S. Patents and U.S. Patent application publications are not enclosed herewith.

The items identified in this Supplemental Information Disclosure Statement may or may not be "material" pursuant to 37 CFR § 1.56 and the submission thereof by Applicant shall not be construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 CFR § 1.97(h)), or even qualifies as "prior art" 35 USC § 102 with respect to this invention unless specifically designated by Applicant as such.

The filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information, as defined in 37 CFR § 1.56, exists.

DISCLOSURE

The attached Supplemental IDS is being filed in accordance with 37 CFR §§ 1.97 and 1.98. This IDS is believed to be timely in that it is being submitted under 37 CFR § 1.97(b)(3), that is before the mailing of a first Office Action on the merits. Thus, no petition or fee is required. However, if the undersigned representative of Applicant is in error in this regard, then the Examiner is requested to consider this IDS as filed under § 1.97(c)

The attached Supplemental Information Disclosure Statement is being filed in accordance with 37 CFR §§ 1.97(c) and 1.98. This IDS is being filed after an action on the merits but before a Final Action under § 1.113 or a Notice of Allowance under § 1.311. In the event that this IDS is not received before a Final Action under § 1.113 or a Notice of Allowance under § 1.311, the Applicant respectfully requests the filing of these papers to be considered a petition requesting consideration of this IDS pursuant to 37 CFR § 1.97(d).

The attached Supplemental Information Disclosure Statement is being filed in accordance with 37 CFR §§ 1.97(d) and 1.98. This IDS is being filed after receipt of a final action but before receipt of a Notice of Allowance Under § 1.311.

Statement Under 37 C.F.R. 1.97(e)(1) and 1.97(e)(2)

I certify that pursuant to 37 CFR 1.97(e)(1), each item of information contained in this Supplemental Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement.

I certify that pursuant to 37 CFR 1.97(e)(2), no item of information contained in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the best of my knowledge, no item of information contained in this Information Disclosure Statement was known to any individual more than three months prior to the filing of this Information Disclosure Statement.

PAYMENT METHOD

Enclosed is a check to cover the fee pursuant to 37 CFR § 1.17(p).

The Examiner is hereby authorized to charge any fee due with this filing to our Deposit Account No. **50-2613**.

The Examiner is hereby authorized to charge any additional fee(s) required by this paper to our Deposit Account No. **50-2613**.


Respectfully submitted,

PAUL, HASTINGS, JANOFSKY & WALKER

Dated:

Sept 23, 2007

By:


Jane K. Babin
Reg. No. 47,224

P.O. Box 919092
San Diego, California 92191-9092
Telephone: (858) 720-2500
Facsimile: (858) 720-2555



Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>					
Sheet	1	of	3	Examiner Name	To be assigned
				Attorney Docket Number	39038.00002.CIP

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
CI	20030017988			Peri, Krishna G et al.	01-23-2003	
CJ	3,691,016			Ravindra	09-12-1972	
CK	3,969,287			Jaworek; Dieter et al.	07-13-1976	
DL	4,195,128			Hildebrand; Dietrich et al.	03-25-1980	
DM	4,229,537			Hodgins; Leonard T et al.	10-21-1980	
DN	4,247,642			Hirohara; Hideo et al.	01-27-1981	
DO	4,330,440			Ayers; John S. et al.	05-18-1982	
DP	4,522,752			Sisto; Alessandro et al.	06-11-1985	
DQ	5,508,384			Murphy; Randall B. et al.	04-16-1996	
DR	5,605,814			Abramovitz; Mark et al.	02-25-1997	
DS	5,688,938			Brown et al.	11-18-1997	
DT	5,759,789			Abramovitz; Mark et al.	06-02-1998	
DU	5,955,575			Peri; Krishna G. et al.	09-21-1999	
DV	6,300,312			Chemtob; Sylvain et al.	10-9-2001	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
DW	WO	93/09104			Hagen et al.	05-13-1993		
DX	WO	95/00551			Abramovitz et al.	01-05-1995		
DY	WO	96/23225			Sundelin et al.	08-01-1996		

Examiner Signature	SAN/98156.1	Date Considered
--------------------	-------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete if Known

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

3

Application Number	10/678,413
Filing Date	October 02, 2003
First Named Inventor	Sylvain, Chemtob et al.
Group Art Unit	1614
Examiner Name	To be assigned
Attorney Docket Number	39038.00002.CIP

NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ²	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ³
	DZ	ABRAMOVITZ, et al. "Cloning and Expression of a cDNA for the Human Prostanoid FP Receptor" Journal of Biol. Chem. Vol. 269, No. 4 pp. 2632-2636, January 28, 1994.	
	EA	BERRIDGE, et al. "Changes in the levels of inositol phosphates after agonist-dependent hydrolysis of membrane phosphoinositides" Biochem, J. Vol. 212, pp. 473-482 (1983)	
	EB	COLEMAN, et al "VIII. International Union of Pharmacology Classification of Prostanoid Receptors: Properties, Distribution, and Structure of the Receptors and their Subtypes", Pharmacological Reviews, Vol. 46, No. 2, pp. 205-229 (1999).	
	EC	GRIFFIN et al. "AL-8810: A Novel Prostaglandin F _{2α} Analog with Selective Antagonist Effects at the Prostaglandin F _{2α} (FP) Receptor", The Journal of Pharmacology and Experimental Therapeutics Vol. 290 No. 3, pp. 1278-1284, 1999.	
	ED	GOETZL et al. "Specificity of expression and effects of eicosanoid mediators in normal physiology and human diseases", The FASEB Journal, Vol. 9, pp. 1051-1058, August 1995.	
	EE	KITANAKA, et al. "Phloretin as an Antagonist of Prostaglandin F _{2α} Receptor in Cultured Rat Astrocytes", Journal of Neurochemistry, Vol. 60. No. 2, pp. 704-708, 1993	
	EF	LI et al. "Key Role for cyclooxygenase-2 in PGE ₂ and PGF _{2α} receptor regulation and cerebral blood flow of the newborn", The American Physiological Society, pp. R1283-R1290 (1997).	
	EG	LI et al. "Inhibition of Prostaglandin Synthesis in Newborn Pigs Increases Cerebral Microvessel Prostaglandin F _{2α} and Prostaglandin E ₂ Receptors, Their Second Messengers and Vasoconstrictor Response to Adult Levels", The Journal of Pharmacology and Experimental Therapeutics, Vol. 278, No. 1, pp. 370-377 (1996)	
	EH	POTVIN, et al. "Refractoriness of the gravid rat uterus to tocolytic and biochemical effects of atrial natriuretic peptide" Br. J. Pharmacol., Vol. 100, pp. 341-347 (1990)	
	EI	STRADER, et al. "Structure and Function of G Protein-Coupled Receptors" Annu. Rev. Biochem. 63:101-32 (1994)	
	EJ	SUGIMOTO et al. "Failure of Parturition in Mice Lacking the Prostaglandin F Receptor", Science Vol. 277, pp. 681-683, August 1997.	

Examiner Signature	SAN/98156.1	Date Considered
--------------------	-------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>					
Sheet	3	of	3	Application Number	10/678,413
				Filing Date	October 02, 2003
				First Named Inventor	Sylvain, Chemtob et al.
				Group Art Unit	1614
				Examiner Name	To be assigned
				Attorney Docket Number	39038.00002.CIP

NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	EK	VARMA et al. "Endothelium- and Beta-2 Adrenoreceptor-Independent Relaxation of Rat Aorta by Tyramine and Certain other Phenylethylamines" The Journal of Pharmacology and Experimental Therapeutics, Vol. 265, No. 3, pp. 1096-1104 (1993),	

Examiner Signature	SAN/98156.1	Date Considered
--------------------	-------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.